The short version
Only one company currently supplies this market — there is no backup if it stumbles.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Photrexa Cross-linking Kit
riboflavin 5-phosphate ophthalmic · Kit · Glaukos Corporation
NDC 25357-0025-03 · 2 POUCH in 1 BOX / 1 POUCH in 1 POUCH / 1 SYRINGE, GLASS in 1 POUCH / 1 KIT in 1 SYRINGE, GLASS · NDA · View full market →
One drug, every price
The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.
ⓘ How this was built
Data sources
- CMS NADAC (pharmacy acquisition, weekly)
- CMS Part B ASP quarterly payment limits
- CMS Maximum Fair Prices (IRA negotiated, NDC-level)
- Medicare Part D Spending by Drug (data.cms.gov, name-matched)
- VA FSS / Big4 federal contract prices (va.gov, twice monthly)
- ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
- California SB-17 WAC filings (list price, per package)
Method
Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
- Federal ceiling (Big4)$3,075.14per unitAvedro, Inc. · Jan 1, 2026
- List price (WAC, as filed)$4,560.00per packageGlaukos · Dec 30, 2024
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Estimated fill cost
WAC per package, as filed
$4,560.00
Reported to Texas DSHS · 2026 annual filing · Glaukos Corporation
Manufacturer list price as filed — not what pharmacies actually pay after discounts.
Medicaid spend (2025)
$3.9M
880 prescriptions paid by Medicaid nationally · all Medicaid spend →
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Regulatory
- Application
- NDA203324
- TE code
- —
- Approval date
- Apr 15, 2016
- Patents / exclusivity
- None on file
Shortage history
- Planned discontinuation — Photrexa Cross-linking Kit, Ophthalmic Solution, Kit (NDC 25357-025-03)Jan 20, 2026
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of riboflavin 5-phosphate ophthalmic (Kit)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Glaukos Corporation | Jul 15, 2026 | Aug 31, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Photrexa Cross-linking Kit — NDC 25357-0025-03," retrieved September 3, 2026, https://drugdashboards.com/drug/25357002503.
Free to cite with attribution — see how the data is put together.